Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 16/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3394304 | 0.87 | HIF1A (0.77) | HIF1APTPN1HSP90AA1 | |
| SCHEMBL3394277 | 0.73 | HIF1A (0.57) | HIF1APTPN1 | |
| SCHEMBL3393832 | 0.72 | HIF1A (0.75) | HIF1APTPN1HSP90AA1 | |
| SCHEMBL3390882 | 0.69 | HIF1A (0.53) | HIF1APTPN1 | |
| SCHEMBL13443045 | 0.69 | HIF1A (0.52) | HIF1A | |
| SCHEMBL3391074 | 0.68 | HIF1A (0.52) | HIF1APTPN1HSP90AA1 | |
| SCHEMBL3394245 | 0.67 | CYP19A1 (0.58) | HIF1APTPN1HSP90AA1 | |
| SCHEMBL3394928 | 0.66 | CYP19A1 (0.50) | HIF1APTPN1 | |
| SCHEMBL16694830 | 0.66 | HIF1A (0.52) | HIF1AHSP90AA1 | |
| SCHEMBL1106477 | 0.65 | HIF1A (0.45) | HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041255-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE SKIN DISEASES | YALE UNIVERSITY | 2025-02-06 | — | — | US | claimed |
| US-20100087478-A1 | HIF-1 Inhibitors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-08 | — | — | US | claimed |
| US-20070099952-A1 | Hif-1 inhibitors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-05-03 | — | — | US | claimed |
| EP-4705775-A1 | MONOCARBOXYLIC ACID TRANSPORTER 4 AS A BIOMARKER FOR HYPOXIA DRIVEN TUMOR GROWTH AND TREATMENT | NantBio, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250041255-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE SKIN DISEASES | YALE UNIVERSITY | 2025-02-06 | — | — | US | disclosed |
| US-20240377385-A1 | METHODS AND COMPOSITIONS OF MATTER FOR TREATING CANCER AND PREDICTING RESPONSE TO THERAPY | ICCA INC. | 2024-11-14 | — | — | US | disclosed |
| WO-2024226531-A1 | MONOCARBOXYLIC ACID TRANSPORTER 4 AS A BIOMARKER FOR HYPOXIA DRIVEN TUMOR GROWTH AND TREATMENT | NANTBIO, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20240352533-A1 | Monocarboxylic Acid Transporter 4 as a Biomarker for Hypoxia Driven Tumor Growth and Treatment | NANTBIO, INC. (US) | 2024-10-24 | — | — | US | disclosed |
| EP-4306297-A2 | SYSTEM AND METHOD FOR PRINTING TISSUE | DEKA Products Limited Partnership (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-3484992-B1 | SYSTEM FOR PRINTING TISSUE | DEKA PRODUCTS LP (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20220169963-A1 | System and Method for Printing Tissue | DEKA PRODUCTS LIMITED PARTNERSHIP | 2022-06-02 | — | — | US | disclosed |
| US-11254901-B2 | System and method for printing tissue | DEKA PRODUCTS LIMITED PARTNERSHIP | 2022-02-22 | — | — | US | disclosed |
| US-20100087478-A1 | HIF-1 Inhibitors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-08 | — | — | US | disclosed |
| US-20100087478-A1 | HIF-1 Inhibitors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-08 | — | — | US | disclosed |
| US-20100087478-A1 | HIF-1 Inhibitors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-08 | — | — | US | disclosed |
| US-7652033-B2 | HIF-1 inhibitors | EMORY UNIVERSITY (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652033-B2 | HIF-1 inhibitors | EMORY UNIVERSITY (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652033-B2 | HIF-1 inhibitors | EMORY UNIVERSITY (US) | 2010-01-26 | — | — | US | disclosed |
| US-20070099952-A1 | Hif-1 inhibitors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-05-03 | — | — | US | disclosed |
| US-20070099952-A1 | Hif-1 inhibitors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099952-A1 | Hif-1 inhibitors | HIF1AN, HIF1A, EGLN2 | HIF1A 2/4885PTPN1 3949/4885HSP90AA1 128/4885 |
| US-20250041255-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE SKIN DISEASES | HIF1AN, HIF1A, SSB | HIF1A 2/4885PTPN1 3490/4885HSP90AA1 918/4885 |
| US-20100087478-A1 | HIF-1 Inhibitors | HIF1AN, HIF1A, EGLN2 | HIF1A 2/4885PTPN1 3949/4885HSP90AA1 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.